DERMATA THERAPEUTICS INC

DRMA represents Dermata Therapeutics, a clinical-stage biotechnology company focused on developing treatments for dermatological conditions. Its pipeline includes product candidates aimed at addressing unmet needs in skin diseases. As a clinical-stage company, its activities center on research and development rather than commercial product sales.

DRMA is listed on the Nasdaq Capital Market under the ticker symbol DRMA. Investors can buy and sell shares through brokerage accounts that provide access to U.S. stock exchanges. The listing venue determines regular trading hours and applicable market rules for the security.

The latest price of DRMA stock is not fixed here because it changes throughout each trading session. For the most current quote, check the live price displayed on this page. That figure reflects the latest market data available and may differ from delayed or historical prices.

Volatility for DRMA can be influenced by its status as a clinical-stage biotech company, where pipeline updates, trial results, and financing news may lead to sharp price movements. Trading volume and market conditions can also affect price swings. Historical volatility data, if provided, appears alongside the stock’s price information on this page.

Valuation for DRMA is often assessed using metrics suited to clinical-stage biotech companies, since traditional earnings-based measures may not apply when revenues are limited. Investors may review cash position, research and development spending, pipeline potential, and share count. Compare these factors with peer companies and consider the risks of drug development timelines.

Key risks for DRMA include clinical trial failures, regulatory setbacks, and the need for additional capital to fund research and development. As a small-cap biotech, it may also face limited revenue, competition, and share dilution. Market sentiment and financing conditions can amplify price volatility beyond operational developments.